about
Novel raf kinase protein-protein interactions found by an exhaustive yeast two-hybrid analysisGamma-secretase activating protein is a therapeutic target for Alzheimer's diseaseThe role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate bindingPhosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical ImplicationsDiscovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric DiseasesStabilization of C5a receptor--G-protein interactions through ligand bindingMapping the subsite preferences of protein tyrosine phosphatase PTP-1B using combinatorial chemistry approaches.C5a receptor antagonists.Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides.Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore.A fluorometric assay for peptidyl alpha-amidation activity using high-performance liquid chromatography.Backbone resonance assignment of the 298 amino acid catalytic domain of protein tyrosine phosphatase 1B (PTP1B).The RAF family: an expanding network of post-translational controls and protein-protein interactions.Characterization, crystallization and preliminary crystallographic analysis of human recombinant cyclooxygenase-2.Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation.Effect of chronic desmethylimipramine or electroconvulsive shock on selected brain and platelet neurotransmitter recognition sites.5-Aryl-3-azabicyclo[3.2.0]heptan-6-one ketals, compounds with morphine-like analgesic activity.Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site.Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy.Substrate phosphorylation can inhibit proteolysis by trypsin-like enzymesCovalent attachment of polydeoxythymidylic acid to human erythrocytesIsolation of cell surface proteins by hybridizationCharacterization of the binding of Bolton-Hunter labeled [125I]C5a to human neutrophil, monocyte and U-937 cell membranesProfiling of inhibitors of protein kinase CAllosteric interaction between the site labeled by [3H]imipramine and the serotonin transporter in human plateletsIdentification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidneySerotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranesRadioiodination of transforming growth factor-beta (TGF-beta) in a modified Bolton-Hunter reaction systemSerotonin modulates the dissociation of [3H]imipramine from human platelet recognition sitesDissection of the 66 000-dalton subunit of the acetylcholine receptorPhospholipase D regulation by a physical interaction with the actin-binding protein gelsolinHuman platelet imipramine recognition sites: biochemical and pharmacological characterizationTransmembrane orientation of proteins present in acetylcholine receptor-rich membranes from Torpedo marmorata studied by selective proteolysisConditions for the selective labelling of the 66 000 dalton chain of the acetylcholine receptor by the covalent non-competitive blocker 5-azido-[3H]trimethisoquinSynthesis and analgesic activity of 5-aryl-3-azabicyclo [3.2.0.] heptan-6-one dimethylacetals: compounds with extraordinary morphine-like propertiesHuman brain receptor alterations in suicide victims
P50
Q24296935-CF75C815-D21F-4A7C-B21C-221FFD2FE04AQ24298408-F709319D-2031-42E0-9794-CD2CA129CA68Q24321328-04078EA2-479A-4DB9-83AA-AE6AD3DE1323Q26753116-FC6C36B0-D06C-49E0-9D22-09FC359C613DQ27703643-251AE002-0B40-4791-97D6-955256E0DAC5Q28241039-3E3B3D31-9DBD-464E-8F6E-FCE87B8628C8Q31960332-ADF400B6-6DE8-4028-AD0A-E72DEE0413E1Q33753918-05F81ACC-B13C-42C1-A76A-D269538043B9Q34405914-808D4F21-4ECC-43A2-B763-001A6EFF4BC5Q37166063-BC4EE564-523D-476A-8EA8-8342AF517CB1Q41068210-505679A7-E46E-4720-A975-55BEB1A7413FQ42515895-FE637BE3-B1E5-4478-BD2B-31558312C975Q43227597-E14DF3AA-3437-45AD-9824-B7CDD3382DD7Q43671936-5113CD43-60B4-476B-B2F4-FA452C70250FQ44258189-50789D24-6B74-42EB-88C3-065B9D8DA53BQ47823131-B79119AE-1631-42E6-A205-F0068BB608F8Q47982498-6102452C-B57F-4ACE-8D6C-C942D7698E25Q48032151-B77CF0B8-2774-44D4-896F-C3882C61AE67Q48291279-513AC713-9EE3-45C5-B5C0-A4D598CFFB53Q48517893-4158C588-0845-4EF1-9014-F3C4555F7052Q48679516-F7434962-DB8C-4E5B-A2AD-2AC55C3CB3D2Q52536739-EF42F426-1E25-4FB1-B672-417964DFC65BQ55654009-AD58F1BA-BDBD-42CE-8D0B-DCF4C524989AQ57268872-521BBB59-E8DD-4E1F-996B-FCA4ED40D472Q67379717-2FD55CC5-86D9-4B49-B3E1-391C6D7B33F6Q67405627-D55F3912-DD13-4217-A3BB-261D2B602ABCQ67560594-7230DD5F-873D-47CD-8306-E562D2474BCEQ68076011-7573DED9-034B-4FAF-B16B-F29B44CBFCDBQ68811288-2A60A23B-3A8B-4005-B828-ADB60C01D90BQ70052455-DF1B5A12-40C8-49C8-9772-4168E41AD710Q70076790-65271D69-0C51-48B2-BE80-5F58DD8CC347Q70503558-A10130C6-25AE-49E4-B39D-11FA01E825D1Q70562592-D61677FB-3E7C-43D9-992B-65DDE736A068Q70787563-C07993E7-B492-4942-AC40-EE5023A9AA9DQ71028732-6AF5A38B-1368-45DA-8FEA-E4A62AEF88C8Q71053237-5AEDC8A0-8B77-470F-9699-EEF306EA4092Q71511619-9C98B27F-C21B-480E-A558-13E20CA039DFQ71849825-6B8D70B7-7412-418F-B338-1F4FCECE8D48Q72558661-6040B9E7-0063-45FD-8422-18FB163E20EFQ72954097-51999BCD-9922-42A4-807E-1B2ACC4D124E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lawrence Paul Wennogle
@ast
Lawrence Paul Wennogle
@en
Lawrence Paul Wennogle
@es
Lawrence Paul Wennogle
@nl
Lawrence Paul Wennogle
@sl
type
label
Lawrence Paul Wennogle
@ast
Lawrence Paul Wennogle
@en
Lawrence Paul Wennogle
@es
Lawrence Paul Wennogle
@nl
Lawrence Paul Wennogle
@sl
prefLabel
Lawrence Paul Wennogle
@ast
Lawrence Paul Wennogle
@en
Lawrence Paul Wennogle
@es
Lawrence Paul Wennogle
@nl
Lawrence Paul Wennogle
@sl
P106
P21
P31
P496
0000-0002-3795-409X
P569
2000-01-01T00:00:00Z